Gossamer Bio announced final results of its exchange offer for 5.00% Convertible Senior Notes due 2027, with $181.052 million in principal amount tendered by the extended early tender date. The company exchanged these notes for new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock, and warrants, reducing near-term debt maturity obligations.